Chemotherapy

ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer

Z. C. Xu, Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., Xu, L., Xu, Z. C., Cai, H. Z., Li, X., Xu, W. Z., Xu, T., Yu, B., Zou, Q., and Xu, L., ERCC1 C118T polymorphism has predictive value for platinum-based chemotherapy in patients with late-stage bladder cancer, vol. 15, p. -, 2016.

This study aims to investigate the association between ERCC1 codon C118T polymorphism and the response rate of platinum-based chemotherapy in patients with late-stage bladder cancer. A total of 41 eligible patients histologically confirmed as having stage IV muscle-invasive transitional cell carcinoma of the bladder were treated with platinum-based chemotherapy for 2-6 cycles. The genotypes of patients were determined by PCR amplification of genomic DNA followed by restriction enzyme digestion. Positive responses were categorized as complete and partial responses.

Subscribe to Chemotherapy